CA2430060C - Identification and use of cell surface receptor-binding ligands for the diagnosis and treatment of cancer - Google Patents

Identification and use of cell surface receptor-binding ligands for the diagnosis and treatment of cancer Download PDF

Info

Publication number
CA2430060C
CA2430060C CA2430060A CA2430060A CA2430060C CA 2430060 C CA2430060 C CA 2430060C CA 2430060 A CA2430060 A CA 2430060A CA 2430060 A CA2430060 A CA 2430060A CA 2430060 C CA2430060 C CA 2430060C
Authority
CA
Canada
Prior art keywords
muc1
peptide
cancer
cell
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2430060A
Other languages
English (en)
French (fr)
Other versions
CA2430060A1 (en
Inventor
Cynthia C. Bamdad
R. Shoshana Bamdad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of CA2430060A1 publication Critical patent/CA2430060A1/en
Application granted granted Critical
Publication of CA2430060C publication Critical patent/CA2430060C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Composite Materials (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2430060A 2000-11-27 2001-11-27 Identification and use of cell surface receptor-binding ligands for the diagnosis and treatment of cancer Expired - Lifetime CA2430060C (en)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US25336100P 2000-11-27 2000-11-27
US60/253,361 2000-11-27
US25537000P 2000-12-13 2000-12-13
US60/255,370 2000-12-13
US25602700P 2000-12-15 2000-12-15
US60/256,027 2000-12-15
US25815700P 2000-12-22 2000-12-22
US60/258,157 2000-12-22
US25961501P 2001-01-03 2001-01-03
US60/259,615 2001-01-03
US26018601P 2001-01-05 2001-01-05
US60/260,186 2001-01-05
US26616901P 2001-02-02 2001-02-02
US60/266,169 2001-02-02
US26692901P 2001-02-06 2001-02-06
US60/266,929 2001-02-06
US27809301P 2001-03-23 2001-03-23
US60/278,093 2001-03-23
US28944401P 2001-05-07 2001-05-07
US60/289,444 2001-05-07
US29488701P 2001-05-31 2001-05-31
US60/294,887 2001-05-31
US29827201P 2001-06-14 2001-06-14
US60/298,272 2001-06-14
PCT/US2001/044782 WO2002056022A2 (en) 2000-11-27 2001-11-27 Diagnostics, drug screening and treatment for cancer

Publications (2)

Publication Number Publication Date
CA2430060A1 CA2430060A1 (en) 2002-07-18
CA2430060C true CA2430060C (en) 2015-11-24

Family

ID=27583824

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2430060A Expired - Lifetime CA2430060C (en) 2000-11-27 2001-11-27 Identification and use of cell surface receptor-binding ligands for the diagnosis and treatment of cancer

Country Status (7)

Country Link
US (3) US7700715B2 (enExample)
EP (4) EP1354196B1 (enExample)
JP (4) JP4564714B2 (enExample)
AT (1) ATE481640T1 (enExample)
CA (1) CA2430060C (enExample)
DK (1) DK2322929T3 (enExample)
WO (1) WO2002056022A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148101A1 (en) * 1999-01-23 2005-07-07 Bamdad Cynthia C. Interaction of colloid-immobilized species with species on non-colloidal structures
AU2002216614A1 (en) 2000-10-03 2002-04-15 Minerva Biotechnologies Corporation Electronic detection of interaction based on the interruption of flow
US7700715B2 (en) * 2000-11-27 2010-04-20 Minerva Biotechnologies Corporation Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
AU2002252459A1 (en) * 2001-03-22 2002-10-08 Minerva Biotechnologies Corporation Customized therapeutics and in situ diagnostics
EP1425016B1 (en) * 2001-09-05 2010-06-02 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
US20060280730A1 (en) * 2001-10-12 2006-12-14 Cedars-Sinai Medical Center Induction of apoptosis of malignant cells by activation of calcium-activated potassium channels
US20090118605A1 (en) * 2002-08-30 2009-05-07 Northwestern University Surface-enhanced raman nanobiosensor
US20040180379A1 (en) * 2002-08-30 2004-09-16 Northwestern University Surface-enhanced raman nanobiosensor
CA2499484A1 (en) * 2002-09-19 2004-04-01 Medigene Aktiengesellschaft Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases
JP2007531505A (ja) * 2002-11-27 2007-11-08 ミネルバ バイオオテクノロジーズ コーポレーション 癌（ｍｕｃ１）の診断および治療のための技術および組成物
AU2004212004B2 (en) * 2003-02-13 2008-01-10 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
WO2005007282A2 (en) * 2003-05-13 2005-01-27 Minerva Biotechnologies Corporation Storage and use of colloids
AU2004248187A1 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
DK2363410T3 (en) * 2003-08-26 2018-01-15 Minerva Biotechnologies Corp ISOFORMER OF MUC1
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
CN1984663A (zh) 2004-03-29 2007-06-20 南佛罗里达大学 用曲西瑞宾和相关化合物有效治疗肿瘤和癌症
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
US8859495B2 (en) 2005-03-30 2014-10-14 Minerva Biotechnologies Corporation Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US20070224638A1 (en) * 2006-03-27 2007-09-27 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
US20090092603A1 (en) * 2007-09-25 2009-04-09 Bamdad Cynthia C Early diagnosis and treatment of drug resistance in muc1-positive cancer
JP2012504961A (ja) * 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１＊抗体
KR20160017117A (ko) 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
MX2011013385A (es) * 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
EP3065105B1 (en) * 2009-06-12 2020-04-29 Nikon Corporation Technique for determining the state of a cell aggregation, image processing program and image processing device using the technique, and method for producing a cell aggregation
WO2011013319A1 (ja) * 2009-07-31 2011-02-03 株式会社ニコン 細胞塊の成熟判定手法、この手法を用いた画像処理プログラム及び画像処理装置、並びに細胞塊の製造方法
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
JP5066615B2 (ja) 2011-01-31 2012-11-07 株式会社日立製作所 フェニルボロン酸基と特異的に結合するオリゴペプチド配列
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2768945B1 (en) 2011-10-17 2022-01-05 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
AU2014226650A1 (en) * 2013-03-08 2015-10-01 Curonz Holdings Company Limited Neural regeneration peptides and uses therefor
CN106132992B (zh) 2014-01-29 2020-08-07 达娜-法勃肿瘤研究所公司 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
CN104297442B (zh) * 2014-11-03 2016-08-17 天津中医药大学 内源性小分子物质在快速检测早期心脏毒性方面的应用
US11123366B1 (en) * 2014-12-15 2021-09-21 Children's Hospital Of Orange County Methods, materials, and systems for treating injuries to the central nervous system using light emitting nanoparticles
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
US10617773B2 (en) 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
CA3040637C (en) * 2016-10-17 2023-02-28 Keio University Undifferentiated stem cell-removing agent, and method for removing undifferentiated stem cells
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CN111875712A (zh) * 2020-07-31 2020-11-03 广东昭泰体内生物医药科技有限公司 一种增强型靶向muc1的嵌合抗原受体及其应用
CA3248038A1 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1504A (en) 1840-03-03 Mode osi constructing- bedsteads
US1997A (en) 1841-03-03 Improvement in the mode of rendering fabrics water-proof
US603173A (en) 1898-04-26 Motor
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5108933A (en) * 1988-09-16 1992-04-28 Immunicon Corporation Manipulation of colloids for facilitating magnetic separations
CA2003211A1 (en) * 1988-11-17 1990-05-17 Pei-Xiang Xing Monoclonal antibodies
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6127393A (en) 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US5767135A (en) * 1995-12-29 1998-06-16 Fernandez-Pol; Jose Alberto Antiviral agent
FR2746016B1 (fr) * 1996-03-15 1998-04-17 Combinaisons d'enzymes pour la destruction de cellules proliferatives
US6177393B1 (en) * 1996-12-12 2001-01-23 The Procter & Gamble Company Process for making tabletted detergent compositions
DE69837754T2 (de) * 1997-02-18 2008-02-07 Canji, Inc., San Diego Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
WO2000034783A1 (en) 1998-12-08 2000-06-15 Smithkline Beecham Corporation Methods of screening for agonists and antagonists of the hdpxu17 receptor
CA2360927C (en) * 1999-01-23 2018-03-06 Minerva Biotechnologies Corporation Interaction of colloid-immobilized species with species on non-colloidal structures
JP5122705B2 (ja) 1999-01-25 2013-01-16 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出
US6421389B1 (en) * 1999-07-16 2002-07-16 Time Domain Corporation Baseband signal converter for a wideband impulse radio receiver
DE60028996T2 (de) * 1999-11-12 2007-02-08 The Johns Hopkins University School Of Medicine Behandlung von krebs durch erhöhung des malonyl-coa-spiegels
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
WO2002022685A2 (en) * 2000-09-11 2002-03-21 Kufe Donald W Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
AU2002248909A1 (en) 2000-11-15 2002-05-27 Minerva Biotechnologies Corporation Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
US7700715B2 (en) * 2000-11-27 2010-04-20 Minerva Biotechnologies Corporation Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
WO2002078598A2 (en) 2001-03-29 2002-10-10 Ramot University Authority For Applied Research & Industrial Development Ltd. Peptides and antibodies to muc 1 proteins
EP1425016B1 (en) 2001-09-05 2010-06-02 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
CA2459584A1 (en) 2001-09-05 2003-03-13 Cynthia C. Bamdad Compositions and use thereof in the treatment of cancer
US6716627B2 (en) 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
EP1497649A4 (en) 2002-04-22 2006-03-22 Dyax Corp FOR MUCIN POLYPEPTIDE SPECIFIC ANTIBODIES
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
JP2007531505A (ja) 2002-11-27 2007-11-08 ミネルバ バイオオテクノロジーズ コーポレーション 癌（ｍｕｃ１）の診断および治療のための技術および組成物
US8510225B2 (en) 2004-09-01 2013-08-13 Research In Motion Limited Split channel authenticity queries in multi-party dialog

Also Published As

Publication number Publication date
JP2015044821A (ja) 2015-03-12
US7700715B2 (en) 2010-04-20
US20030036199A1 (en) 2003-02-20
EP2322929A1 (en) 2011-05-18
JP2017081999A (ja) 2017-05-18
JP6124856B2 (ja) 2017-05-10
JP5926474B2 (ja) 2016-05-25
EP2322929B1 (en) 2016-04-06
CA2430060A1 (en) 2002-07-18
JP4564714B2 (ja) 2010-10-20
EP2386859A2 (en) 2011-11-16
EP2386859B1 (en) 2015-11-11
EP2241887A3 (en) 2010-11-03
EP2241887B1 (en) 2015-01-14
WO2002056022A2 (en) 2002-07-18
JP2004534730A (ja) 2004-11-18
WO2002056022A3 (en) 2003-08-21
JP6516778B2 (ja) 2019-05-22
ATE481640T1 (de) 2010-10-15
DK2322929T3 (en) 2016-07-25
EP1354196A2 (en) 2003-10-22
US20100136017A1 (en) 2010-06-03
JP2010106028A (ja) 2010-05-13
US20130323755A1 (en) 2013-12-05
EP2241887A2 (en) 2010-10-20
EP1354196B1 (en) 2010-09-15
US8344113B2 (en) 2013-01-01
EP2386859A3 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
US7700715B2 (en) Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
JP7064275B2 (ja) 診断および治療のための腫瘍関連細胞表面抗原の同定
AU2009213107A1 (en) Techniques and compositions for the diagnosis and treatment of cancer (MUC1)
US20090092603A1 (en) Early diagnosis and treatment of drug resistance in muc1-positive cancer
US20190310255A1 (en) Proteins
CN104066751A (zh) 对聚糖具有高亲和力和选择性的lambody及其用途
EP2185933B1 (en) Matriptase protein and uses thereof
US20060173171A1 (en) Techniques and compositions for diagnosis and treatment of cancer (muci)
AU2002243251A1 (en) Diagnostics, drug screening and treatment for cancer
JP6111018B2 (ja) 癌（ｍｕｃ１）の診断および治療のための技術および組成物
AU2004267112B2 (en) Techniques and compositions for the diagnosis and treatment of cancer (MUC1)
JP2011522872A (ja) エフリンａ型受容体７タンパク質

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20211129